Consensus 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.26 ^USD	+0.12%		-9.03%	-26.05%

Apr. 17	89bio, Inc. Appoints Martin Babler to Its Board of Directors	CI
Apr. 03	89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	MT

Evolution of the average Target Price on 89bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8.oEtGWtRVVACN1ZB9ZfhRLMOnydhAm0EwGjniqczEvk8.1ihzP5U3Zme4n_1FOpZoaIbu8L856XF9KWbRmPr36mLUHhw8lxcWV-Km8w~01e3ddf6b0949eea77bcf8c4b792f21d

Analyst Recommendations on 89bio, Inc.

89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	Apr. 03	MT
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating	Mar. 07	MT
HC Wainwright Cuts Price Target on 89bio to $31 From $32, Keeps Buy Rating	Mar. 01	MT
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk	Mar. 01	MT
RBC Downgrades 89bio to Sector Perform From Outperform, Cuts Price Target to $15 From $24 on View for 'Quieter Year,' Keeps Speculative Risk	Jan. 12	MT
HC Wainwright Cuts 89bio Price Target to $32 From $35, Maintains Buy Rating	Dec. 20	MT
RBC Cuts Price Target on 89bio to $24 From $27, Keeps Outperform, Speculative Risk	Nov. 09	MT
UBS Cuts 89bio Price Target to $25 From $36, Maintains Buy Rating	23-10-12	MT
RBC Cuts Price Target on 89bio to $27 From $34 Amid 'Negative Read-Through' From 'Disappointing' Akero Data; Outperform, Speculative Risk Kept	23-10-11	MT
UBS Initiates Coverage on 89bio With Buy Rating, $36 Price Target	23-08-28	MT
Oppenheimer Cuts 89bio's Price Target to $30 From $33, Maintains Outperform Rating	23-08-16	MT
Cantor Fitzgerald Cuts Price Target on 89bio to $39 From $41, Maintains Overweight Rating	23-08-10	MT
RBC Lifts Price Target on 89bio to $34 From $33, Keeps Rating at Outperform, Speculative Risk	23-08-10	MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	23-07-07	DJ
BTIG Adjusts Price Target on 89bio to $37 From $30, Maintains Buy Rating	23-07-03	MT
Evercore ISI Initiates 89bio at Outperform With $49 Price Target	23-06-13	MT
HC Wainwright Adjusts 89bio's Price Target to $35 From $30, Keeps Buy Rating	23-05-08	MT
RBC Cuts Price Target on 89bio to $33 From $36, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-05	MT
HC Wainwright Adjusts Price Target on 89bio to $30 From $25, Keeps Buy Rating	23-03-23	MT
RBC Capital Adjusts 89bio Price Target to $36 From $27, Maintains Outperform Rating	23-03-22	MT
Raymond James Adjusts Price Target on 89bio to $50 From $25, Maintains Strong Buy Rating	23-03-22	MT
Cantor Fitzgerald Adjusts 89bio's Price Target to $45 From $34, Keeps Overweight Rating	23-03-22	MT
HC Wainwright Adjusts Price Target on 89bio to $25 From $27, Maintains Buy Rating	23-03-20	MT
Oppenheimer Adjusts 89bio's Price Target to $18 From $12, Maintains Outperform Rating	23-02-21	MT
RBC Cuts Price Target on 89bio to $27 From $29, Maintains Outperform Rating	23-01-13	MT